ABSTRACT
INTRODUCTION AND AIMS: Take-home naloxone (THN) programs commenced in Australia in 2012 in the Australian Capital Territory and programs now operate in five Australian jurisdictions. The purpose of this paper is to record the progress of THN programs in Australia, to provide a resource for others wanting to start THN projects, and provide a tool for policy makers and others considering expansion of THN programs in this country and elsewhere. DESIGN AND METHODS: Key stakeholders with principal responsibility for identified THN programs operating in Australia provided descriptions of program development, implementation and characteristics. Short summaries of known THN programs from each jurisdiction are provided along with a table detailing program characteristics and outcomes. RESULTS: Data collected across current Australian THN programs suggest that to date over 2500 Australians at risk of overdose have been trained and provided naloxone. Evaluation data from four programs recorded 146 overdose reversals involving naloxone that was given by THN participants. DISCUSSION AND CONCLUSIONS: Peer drug user groups currently play a central role in the development, delivery and scale-up of THN in Australia. Health professionals who work with people who use illicit opioids are increasingly taking part as alcohol and other drug-related health agencies have recognised the opportunity for THN provision through interactions with their clients. Australia has made rapid progress in removing regulatory barriers to naloxone since the initiation of the first THN program in 2012. However, logistical and economic barriers remain and further work is needed to expand access to this life-saving medication.
Subject(s)
Drug Overdose/drug therapy , Drug Users , Harm Reduction , Naloxone/therapeutic use , Narcotic Antagonists/therapeutic use , Australia , Humans , Program Development , Program EvaluationABSTRACT
ISSUES: Addiction treatment providers' views about the disease model of addiction (DMA), and their contemporary views about the brain disease model of addiction (BDMA), remain an understudied area. We systematically reviewed treatment providers' attitudes about the DMA/BDMA, examined factors associated with positive or negative attitudes and assessed their views on the potential clinical impact of both models. APPROACH: Pubmed, EMBASE, PsycINFO, CINAHL Plus and Sociological Abstracts were systematically searched. Original papers on treatment providers' views about the DMA/BDMA and its clinical impact were included. Studies focussing on tobacco, behavioural addictions or non-Western populations were excluded. KEY FINDINGS: The 34 included studies were predominantly quantitative and conducted in the USA. Among mixed findings of treatment providers' support for the DMA, strong validity studies indicated treatment providers supported the disease concept and moral, free-will or social models simultaneously. Support for the DMA was positively associated with treatment providers' age, year of qualification, certification status, religious beliefs, being in recovery and Alcoholics Anonymous attendance. Greater education was negatively associated with DMA support. Treatment providers identified potential positive (e.g. reduced stigma) and negative (e.g. increased sense of helplessness) impacts of the DMA on client behaviour. IMPLICATIONS/CONCLUSION: The review suggests treatment providers may endorse disease and other models while strategically deploying the DMA for presumed therapeutic benefits. Varying DMA support across workforces indicated service users may experience multiple and potentially contradictory explanations of addiction. Future policy development will benefit by considering how treatment providers adopt disease concepts in practice.
Subject(s)
Attitude of Health Personnel , Behavior, Addictive/therapy , Health Knowledge, Attitudes, Practice , Models, Theoretical , Substance-Related Disorders/therapy , HumansSubject(s)
Doping in Sports/ethics , Harm Reduction , Sports , Bioethical Issues , Dissent and Disputes , HumansABSTRACT
The concepts of 'biopolitics' and 'naked life' have become increasingly relevant in the debate on substance dependency due to the growing prominence of neuroscience in defining the nature of addiction and its threat to agency. However, these concepts are not necessarily well understood, and therefore may lead to oversight rather than insight. In this article we review the literature on Italian philosopher Giorgio Agamben, whose founding works on both concepts shed a different light on addiction. We argue that the current debate is missing a key insight from Agamben's work: the idea of agency past the subject, of agency past identity. We will illustrate how this can be an important form of agency against the stigmatization of users, making use of empirical data from our ongoing work on addiction and agency.
Subject(s)
Behavior, Addictive , Bioethical Issues , Drug Users , Personal Autonomy , Social Stigma , Substance-Related Disorders , Humans , Qualitative ResearchABSTRACT
OBJECTIVES: The objective was to examine the effect of endotracheal intubation on emergency department (ED) length of stay (LOS) and admission rates for patients with gamma-hydroxybutyrate (GHB) overdose. METHODS: A 3-year retrospective electronic and paper audit of recreational drug presentations was carried out at two major inner-city EDs in Melbourne, Australia. Different GHB overdose management strategies exist at the respective audit sites, namely: 1) all patients with a Glasgow Coma Scale (GCS) score of 8 or less are intubated or 2) uncomplicated patients with GCS scores of 8 or less are managed without intubation (conservative management), unless further complications arise. This difference allows for comparison of the effects of intubation. All suspected GHB-related cases (defined as cases where GHB or its analogs gamma-butyrolactone or 1,4-butanediol were recorded) in which altered consciousness state was noted as a presenting symptom at triage were selected from all recreational drug-related presentations occurring between January 2008 and December 2010. The relationship between intubation and the primary outcome, ED LOS, was examined using robust regression after adjustment for potential confounders. The relationship between intubation and admission status (admission to hospital versus discharge) was also examined using logistic regression. RESULTS: After adjustment for potential confounders such as GCS score, intubation of GHB-related cases in the ED was associated with an increase in mean LOS of 41% (95% confidence interval [CI] = 19% to 65%) and an increase in the odds of admission to hospital of 9.95 (95% CI = 2.36 to 41.88) at one hospital site, compared to conservative airway management. CONCLUSIONS: Conservative airway management (no intubation) is associated with shorter ED LOS in cases of uncomplicated GHB-related coma in the ED and may also be associated with lower admission rates for these patients.
Subject(s)
Drug Overdose/therapy , Emergency Service, Hospital , Intubation, Intratracheal/methods , Length of Stay/trends , Sodium Oxybate/adverse effects , Adult , Anesthetics, Intravenous/adverse effects , Female , Follow-Up Studies , Glasgow Coma Scale , Humans , Male , Retrospective Studies , Sodium Oxybate/administration & dosage , Treatment Outcome , Young AdultABSTRACT
Beyond the usual technical and evidentiary considerations, there are ethical questions that we must consider in the justification of our obesity interventions in the name of expected population health gains. These relate to the types of health identities that are permitted in society, the possible unintended consequences of preferencing certain health identities over others, and the manner in which public health policies and interventions are justified. The prevalence of overweight and obesity in Australia highlights some of the areas of uncertainty and identifies some important ethical questions that arise as a result of this uncertainty. I propose that the Australian obesity prevention strategy could be evaluated using the Nuffield Council on Bioethics stewardship model of public health to assess whether any current approaches exceed recommended intervention constraints or limits. My aim is to prompt further debate on this topic.
Subject(s)
Health Policy , Obesity , Public Health/ethics , Australia/epidemiology , Bioethics , Government Programs/ethics , Humans , Obesity/epidemiology , Obesity/prevention & control , Overweight/epidemiology , Overweight/prevention & controlABSTRACT
The national health reform reviews conducted recently in Australia ('Henry Review', National Preventative Health Taskforce, National Health and Hospitals Reform Commission) have seen significant energy invested in articulating a new vision for health promotion and disease prevention in this country. This is an opportune time to think critically about the underpinning frameworks that we want to guide our decisions and actions in public health policy, practice and research. The purpose of this piece is to raise questions for debate in relation to the issues of competing professional interests and perspectives, intervention limits, permissible health identities; and what these might mean for the justification of health promotion and prevention interventions in a changing funding and policy environment.
Subject(s)
Health Promotion/organization & administration , Primary Prevention/organization & administration , Australia , Cooperative Behavior , Health Policy , Health Promotion/legislation & jurisprudence , Humans , Politics , Primary Prevention/ethics , Primary Prevention/legislation & jurisprudence , Public Health PracticeSubject(s)
Allied Health Occupations/education , Education, Professional/methods , Ethics, Clinical/education , Pediatrics/ethics , Teaching/methods , Allied Health Occupations/ethics , Allied Health Occupations/standards , Allied Health Occupations/trends , Child , Decision Making/ethics , Education, Professional/standards , Education, Professional/trends , Health Knowledge, Attitudes, Practice , Humans , Pediatrics/standards , Pediatrics/trends , Research/trends , Teaching/standards , Teaching/trendsSubject(s)
Community-Based Participatory Research/ethics , Guidelines as Topic , Patient Selection/ethics , Peer Group , Public Health , Research/organization & administration , Coercion , Community-Based Participatory Research/methods , Community-Based Participatory Research/organization & administration , Ethical Analysis , Ethics, Research , Humans , Informed Consent/ethics , Research Design/trends , Sampling StudiesABSTRACT
The usage of Ecstasy and related drug (ERD) has increasingly been the focus of epidemiological and other public health-related research. One of the more promising methods is the use of the Internet as a recruitment and survey tool. However, there remain methodological concerns and questions about representativeness. Three samples of ERD users in Melbourne, Australia surveyed in 2004 are compared in terms of a number of key demographic and drug use variables. The Internet, face-to-face, and probability sampling methods appear to access similar but not identical groups of ERD users. Implications and limitations of the study are noted and future research is recommended.
Subject(s)
Drug Users/statistics & numerical data , Epidemiologic Methods , Health Surveys , Internet , Substance-Related Disorders/epidemiology , Adolescent , Adult , Female , Humans , Illicit Drugs , Male , Middle Aged , N-Methyl-3,4-methylenedioxyamphetamine/administration & dosage , Sampling StudiesSubject(s)
Bioethics/trends , Empirical Research , Ethical Analysis , Ethical Theory , Bioethical Issues , HumansABSTRACT
INTRODUCTION AND AIMS: To examine age-related differences in drug use and risk among regular injecting drug users (IDU) in Australia. DESIGN AND METHODS: Cross-sectional data from the 2006 Illicit Drug Reporting System were examined for age-related differences in demographic characteristics, drug use history and current use patterns and self-reported risk behaviours. RESULTS: IDU under 25 years of age were more likely to have initiated injecting at a younger age, to identify as Aboriginal and/or Torres Strait Islander, and to be injecting daily or more often than their older counterparts. They reported more frequent heroin use in the preceding 6 months, and were more likely to report morphine as the first drug injected than were IDU aged 35 years or over. Younger IDU were also more likely to report providing used needles to others, engaging in recent property crime and drug dealing and arrest in the last year. CONCLUSIONS: Younger IDU reported significantly different drug use patterns and higher rates of risk behaviours than their older counterparts. Treatment services need to ensure that harm and demand reduction services deliver messages to new cohorts of IDU, particularly given that their drug use patterns may be different to those of older users.
Subject(s)
Illicit Drugs/adverse effects , Risk-Taking , Substance Abuse, Intravenous/epidemiology , Adult , Age Factors , Australia , Crime/statistics & numerical data , Cross-Sectional Studies , Data Collection , Equipment Reuse/statistics & numerical data , Female , Harm Reduction , Heroin/adverse effects , Humans , Male , Morphine/adverse effects , Native Hawaiian or Other Pacific Islander , Substance Abuse, Intravenous/ethnologyABSTRACT
BACKGROUND: The hepatitis C virus (HCV) is a major cause of drug-related morbidity and mortality, with incidence data implicating a wide range of HCV transmission risk practices. The Blood-Borne Virus Transmission Risk Assessment Questionnaire (BBV-TRAQ) is a content valid instrument that comprehensively assesses HCV risk practices. This study examines the properties of a new weighted BBV-TRAQ designed to quantify HCV transmission risk among injecting drug users (IDU). METHODS: Analyses of cross-sectional surveys of Australian IDU (N = 450) were used to generate normative data and explore the properties of a weighted BBV-TRAQ. Items weights were assigned according to expert key informant ratings of HCV risk practices performed during the development stages of the BBV-TRAQ. A range of item weights was tested and psychometric properties explored. A weighting scheme was recommended based on the plausibility of normative subscale data in relation to research evidence and the ability of BBV-TRAQ scores to discriminate between HCV positive and negative participants. RESULTS: While retaining the psychometric properties of the unweighted scale and demonstrating good internal reliability. By taking into account the relative transmission risk of a broad range of putative HCV practices, the weighted BBV-TRAQ produced promising predictive validity results among IDU based on self-report HCV status, particularly among young and less experienced injectors. CONCLUSION: Brief, easy to administer and score, and inexpensive to apply, the utility of the BBV-TRAQ for community based education and prevention is enhanced by the application of item weights, potentially offering a valid surrogate measure for HCV infection among IDU.